TACH101: First-in-class KDM4-targeted Therapy

TACH101 is an oral, selective, first-in-class, potent small-molecule inhibitor of KDM4 discovered through a proprietary and unique single-cell genomic analysis technology. TACH101 is effective at inhibiting all members of the KDM4 family of proteins.

In preclinical studies, TACH101 was shown to block the proliferation of multiple cancer cell lines as well as patient-derived organoid models (3D tissue cultures formed from cancer stem cells). In addition, TACH101 treatment reduced tumor growth by up to 100% in animal xenograft models representing various cancer types, such as colorectal, esophageal, breast, and lymphoma. Most importantly, TACH101 was shown to reduce the number of tumor-initiating cancer stem cells responsible for relapses and metastases and that are particularly resistant to chemotherapy.

TACH101 is being developed for the treatment of advanced or metastatic cancers. A first-in-human Phase 1 clinical trial is currently ongoing (NCT05076552).

TACH204: LEFTY1 Inhibitor

Tachyon has partnered with AbCellera Biologics Inc. to develop TACH204, a monoclonal antibody to inhibit LEFTY1. We believe that TACH204 may interfere with the ability of LEFTY1 to drive the growth of malignant epithelial stem cells and breast cancer development. TACH204 is currently in discovery phase.